ArticleDiscovery medicine2013
Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.
Article in Discovery medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 44 citations in OpenAlex.
- CXCL14 Inhibits Colon Cancer Progression by Modulating Tumor Cell Invasion and Immune Microenvironment.Cells · 2026Article
- Potential of Selected C-X-C Motif Chemokines as Biomarkers in Colorectal Cancer Diagnosis.International journal of molecular sciences · 2025Review
- Transcriptome Analysis of Porphyromonas gingivalis Lipopolysaccharide-Induced Early Gene Expression in Human Gingival Keratinocytes.Journal of periodontal research · 2025Article
- Multi-omics modality completion and knowledge distillation for drug response prediction in cervical cancer.Frontiers in oncology · 2025Article
- Review
- Data Mining Suggests That CXCL14 Gene Silencing in Colon Cancer Is Due to Promoter Methylation.International journal of molecular sciences · 2023Article
- CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.Scientific reports · 2023Article
- A Novel Approach to Staging and Detection of Colorectal Cancer in Early Stages.Journal of clinical medicine · 2023Article
- Emerging Role of Plant-Based Dietary Components in Post-Translational Modifications Associated with Colorectal Cancer.Life (Basel, Switzerland) · 2023Review
- Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer.Frontiers in pharmacology · 2022Review
- A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs.Oncotarget · 2021Article
- Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.Cancer science · 2021Article
- Crosstalk Between Inflammatory Signaling and Methylation in Cancer.Frontiers in cell and developmental biology · 2021Review
- Intratumor Epigenetic Heterogeneity-A Panel Gene Methylation Study in Thyroid Cancer.Frontiers in genetics · 2021Article
- The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.Molecular carcinogenesis · 2020Review
- Identification of aberrantly methylated differentially expressed genes targeted by differentially expressed miRNA in osteosarcoma.Annals of translational medicine · 2020Article
- Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling.Clinical epigenetics · 2020Article
- The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome.International journal of molecular sciences · 2019Article
- C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression.International journal of molecular sciences · 2019Review
- Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
To explore epigenetic regulation and the impact of chemokine CXCL14 on colorectal cancer, 7 colorectal cancer cell lines, 107 cases of primary colorectal cancer, and 10 cases of normal colorectal mucosa were evaluated in this study. Methylation specific PCR (MSP), semi-quantitative reverse-transcription PCR (RT-PCR), cell proliferation assay, colony formation, and transwell assay were performed for the evaluation. Complete methylation and loss of CXCL14 expression were found in 5 colorectal cancer cell lines. Partial methylation and weak expression were found in two cell lines. CXCL14 was methylated in 79.4% (85/107) of primary human colorectal cancer. No methylation was found in 10 cases of normal colorectal mucosa. Restoration of CXCL14 expression was induced by the 5-aza-2'-deoxycytidine (DAC) treatment. The cell viability was reduced and colony formation was inhibited by restoration of CXCL14 expression in HCT116 cells, a colorectal cancer cell line. The number of invasive and migration cells was reduced by CXCL14. The expression of MMP-2, Vimentin, and NF-κB was suppressed, and the expression of E-cadherin and IκB-α was induced by CXCL14. In conclusion, CXCL14 is frequently methylated in human colorectal cancer and promoter region hypermethylation silenced CXCL14 expression in colorectal cancer cells. Restoration of CXCL14 expression suppressed colorectal cancer proliferation. CXCL14 inhibits colorectal cancer migration, invasion, and epithelial-to-mesenchymal transition (EMT) by suppressing NF-κB signaling.
Indexed as
Identifiers
24099668PMC4061567W198339934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.